Pin Zhang

Bing-he Xu, P. Yuan, Jiayu Wang, 2013, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Bing-he Xu, P. Yuan, F. Ma, 2016, Oncotarget.

A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer

D. Lin, Dianke Yu, F. Du, 2016, Oncotarget.

Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial.

Yang Luo, Bing-he Xu, Z. Shao, 2021, JAMA oncology.

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study

Yang Luo, Bing-he Xu, P. Yuan, 2019, Oncology letters.

Development and External Validation of a Clinical Nomogram for Individually Predicting Survival of Metaplastic Breast Cancer.

Yang Luo, Bing-he Xu, F. Ma, 2022, Clinical breast cancer.

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy

Bing-he Xu, P. Yuan, F. Ma, 2012, Breast Cancer Research and Treatment.

Decreased Serum HDL at Initial Diagnosis Correlates with Worse Outcomes for Triple-Negative Breast Cancer but Not Non-TNBCs

Bing-he Xu, P. Yuan, F. Ma, 2015, The International journal of biological markers.

Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy.

Peng Yuan, Pin Zhang, Fei Ma, 2012, Chinese medical journal.

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer

Yang Luo, Bing-he Xu, F. Ma, 2019, Cancer communications.

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

G. Lippi, Yang Luo, Bing-he Xu, 2021, Cancer biology & medicine.

A nation-wide multicenter 10-year (1999–2008) retrospective study of chemotherapy in Chinese breast cancer patients

Y. Qiao, Jin-Hu Fan, Xiaoming Xie, 2016, Oncotarget.

Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.

Bing-he Xu, P. Yuan, F. Ma, 2011, Endocrine journal.

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Yongmei Yin, Bing-he Xu, Huiping Li, 2017, The Lancet. Oncology.

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Peng Yuan, Jiayu Wang, Pin Zhang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients

Yang Luo, Bing-he Xu, P. Yuan, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer

Yang Luo, Bing-he Xu, Yun Wu, 2022, Breast Cancer Research and Treatment.

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis

Yang Luo, Bing-he Xu, P. Yuan, 2019, Cancer management and research.

CMAR_A_198962 4699..4706

Yang Luo, Bing-he Xu, P. Yuan, 2019 .

Conditional cause-specific survival after chemotherapy and local treatment for primary stage IV breast cancer: A population-based study

Pin Zhang, Min Xiao, 2022, Frontiers in Oncology.

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China

Yang Luo, Bing-he Xu, P. Yuan, 2021, Breast.

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China

Yang Luo, Bing-he Xu, P. Yuan, 2020, Breast.

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer

Yang Luo, Bing-he Xu, P. Yuan, 2015, Medicine.

Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study.

Y. Qiao, Jin-Hu Fan, Wei Zhang, 2021, Gland surgery.

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

Yang Luo, Bing-he Xu, Jifeng Feng, 2021 .

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population

Yang Luo, Bing-he Xu, P. Yuan, 2021, Frontiers in Oncology.

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China.

Yang Luo, Bing-he Xu, P. Yuan, 2020 .

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

Yang Luo, Bing-he Xu, P. Yuan, 2019, Cancer communications.

Docetaxel Plus S-1 versus Docetaxel Plus Capecitabine as First-Line Treatment for Advanced Breast Cancer Patients: A Prospective Randomized Phase II Study

Yang Luo, Bing-he Xu, P. Yuan, 2023, Journal of the National Cancer Center.

Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.

Bing-he Xu, P. Yuan, F. Ma, 2012, Breast.

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

Yang Luo, Bing-he Xu, F. Ma, 2023, Biomarker Research.

Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China

Wen-na Wang, Yang Luo, Bing-he Xu, 2018, International journal of cancer.

Paclitaxel plus carboplatin for women with advanced breast cancer.

Bing-he Xu, Long-Mei Zhao, Jiayu Wang, 2007, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].

Bing-he Xu, P. Yuan, F. Ma, 2014, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life

Yang Luo, Bing-he Xu, P. Yuan, 2020, Annals of Surgical Oncology.

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population

Yang Luo, Bing-he Xu, P. Yuan, 2016, Medicine.

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first‐line treatment of patients with advanced breast cancer: Phase 3 randomized trial

Yang Luo, Bing-he Xu, P. Yuan, 2015, Cancer.

A Prospective, Randomized, Placebo-Controlled Study Assessing the Efficacy of Chinese Herbal Medicine (Huangqi Guizhi Wuwu Decoction) in the Treatment of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy

Wen-na Wang, Bing-he Xu, Y. Chai, 2023, Journal of clinical medicine.

Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors

Bing-he Xu, Li Tang, G. Dou, 2011, Cancer Chemotherapy and Pharmacology.

63O A nation-wide multicenter 10-Year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients

Y. Qiao, Jin-Hu Fan, Hongyu Li, 2016 .

Epidemiologic study of radiotherapy use in China in patients with breast cancer between 1999 and 2008.

Y. Qiao, Jin-Hu Fan, Jiayuan Li, 2013, Clinical breast cancer.

[Clinical features and prognosis in breast cancer patients over 70 years of age].

Bing-he Xu, Yan Sun, Pin Zhang, 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Body Mass Index and Breast Cancer Defined by Biological Receptor Status in Pre-Menopausal and Post-Menopausal Women: A Multicenter Study in China

Y. Qiao, Jin-Hu Fan, Jiayuan Li, 2014, PloS one.

Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts

Yang Luo, Bing-he Xu, P. Yuan, 2017, Oncotarget.

Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis.

Yanxia Sun, Yang Luo, Bing-he Xu, 2020, Clinical breast cancer.

Diagnosis and guidance of treatment of breast cancer cutaneous metastases by multiple needle biopsy: A case report

P. Xue, Pin Zhang, Shijie Zhu, 2022, World journal of clinical cases.

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer

Yang Luo, Bing-he Xu, F. Ma, 2023, Signal Transduction and Targeted Therapy.

Epidemiology and clinicopathologic features of breast cancer in China and the United States

X. Zou, Xi Chen, Yang Liu, 2023, Translational cancer research.

TNM stage at diagnosis is more predictive of prognosis than pathological complete response in young breast cancer treated with neoadjuvant chemotherapy

Yang Luo, Bing-he Xu, P. Yuan, 2017, Anti-cancer drugs.

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population

Yang Luo, Bing-he Xu, P. Yuan, 2018, International journal of cancer.

Icaritin efficacy and tolerability in advanced hepatocellular carcinoma: Final phase Ib result.

Bing-he Xu, P. Yuan, Kun Meng, 2014 .

Serum Dickkopf-1 levels as a clinical and prognostic factor in patients with bladder cancer.

P. Zhang, L. Wang, J. Wang, 2015, Genetics and molecular research : GMR.

Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study

Pin Zhang, Xi Chen, Xiaoyan Qian, 2023, Breast cancer.

Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine

Bing-he Xu, P. Yuan, J. Ju, 2023, Cancer biology & medicine.

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Y. Wang, Ying Cheng, Bing-he Xu, 2023, The Lancet. Oncology.

Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.

Pin Zhang, M. Xiu, Shan-shan Chen, 2024, British journal of clinical pharmacology.